Results 111 to 120 of about 543 (171)

New drugs and their performance 10 years after approval: a systematic analysis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Manfouo B, Seifert R.
europepmc   +1 more source

National guidelines for gastric cancer: redundant or needed? [PDF]

Gastric Cancer
Lordick F, Wörmann B.
europepmc   +1 more source

Towards a Unified European View of Clinical Evidence: What 'Health Technology Assessment Organizations' Can Learn from Regulatory Experience. [PDF]

J Mark Access Health Policy
Broich K, Löbker W.
europepmc   +1 more source

Healthcare effects and evidence robustness of reimbursable digital health applications in Germany: a systematic review. [PDF]

NPJ Digit Med
Sippli K, Deckert S, Schmitt J, Scheibe M.   +3 more
europepmc   +1 more source

PTX-loaded, polysorbate 80-functionalized brain-targeting pullulan nanoparticles for drug delivery. [PDF]

Front Pharmacol
Yuan H, Han L, Deng H, Tan Y, Yang Y, Liu Y, Ying J, Fang M, Wei H, Tao Z.   +9 more
europepmc   +1 more source

Beyond Numbers: Uses and Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision Making. [PDF]

Patient
Dias-Barbosa C, Kimel M, Rolska-Wojcik P, Bailey K, Eseyin OR, Martin ML.   +5 more
europepmc   +1 more source

Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a review. [PDF]

Front Oncol
Ruge L, Verheyen M, John F, Wolf J.
europepmc   +1 more source

AMNOG: Ziel, Funktionsweise und Ergebnisse

Melanie Schröder, Anja Tebinka-Olbrich, Antje Haas   +2 more
openaire   +1 more source